Influencia de la incorporación de la mujer a las redacciones en las audiencias de prensa

La presencia de la mujer en los medios de comunicación es escasa y limitada y no refleja el lugar que ocupa en la sociedad. Desde el I+D+i SANIMUEI, con financiación del Instituto de la Mujer, pretendemos encontrar las claves que permitan entender por qué existen medios cuyos índices de lectura femenino duplican al de otros y en qué medida sus contenidos justifican esos desniveles. Para ello esta comunicación busca cuantificar la presencia de las mujeres en las redacciones de los medios, para de este modo comprender cómo esto incide en la mayor o menor presencia de temas femeninos en las páginas de los mismos. Hemos seleccionado los tres periódicos que según los estudios de audiencia segregados por sexos tienen un mayor índice de lectoras y los tres que tienen un menor índice en la Comunidad de Andalucía. La cuantificación de firmas femeninas totales de los medios y su distribución por secciones, así como las firmas de las imágenes nos permitirá establecer relaciones entre la presencia de temas protagonizados por mujeres y las firmas de las periodistas y si la presencia visual está relacionada con la de autoras de fotografías. Avanzamos así en un estudio que busca relaciones e interacciones entre las empresas, las redacciones, los contenidos y las audiencias

A Full Vacuum Approach for the Fabrication of Hybrid White-Light-Emitting Thin Films and Wide-Range In Situ Tunable Luminescent Microcavities

This study shows the fabrication by a dry approach at mild temperature (<150 °C) of a photoluminescence white light emitting hybrid layer. The white light emitter is obtained by evaporation of two photoluminescent small molecules, a blue (1,3,5-triphenyl-2-pyrazoline (TPP)) and an orange (Rubrene) dye within the porous of an SiO host film fabricated by glancing angle deposition. Fluorescence (Föster) resonant energy transfer between the two organic dyes allows the emission of the combined system upon excitation of the TPP molecule at wavelength of 365 nm. The distribution of the organic molecule within the host layer is analyzed as a function of the substrate temperature and vacuum conditions and the required conditions for the white emission determined by finely controlling the TPP:Rubrene ratio. The full vacuum processing of the hybrid layers provides a straightforward route for the incorporation of the white light emitters as optical defect within 1D Bragg microcavities. As a consequence, directional emission of the system is achieved which allows the development of wide-range in situ tunable photoluminescent devices.Junta de Andalucía TEP8067, FQM-6900, P12-FQM-2265Ministerio de Economía y Competitividad MAT2013-40852-R, MAT2013-42900-

Detector de partículas ionizantes

Detector de partículas ionizantes. El objeto de la presente invención es un sensor de radiación ionizante con energías comprendidas entre 0.1 keV y 100 MeV sensible tanto al tipo de radiación como a su energía. El detector comprende una estructura apilada de varias capas de material con distintos luminiscentesEspañ

Real-world experience with bezlotoxumab for prevention of recurrence of Clostridioides difficile infection

Bezlotoxumab is marketed for the prevention of recurrent Clostridioides difficile infection (rCDI). Its high cost could be determining its prescription to a different population than that represented in clinical trials. The objective of the study was to verify the effectiveness and safety of bezlotoxumab in preventing rCDI and to investigate factors related to bezlotoxumab failure in the real world. A retrospective, multicentre cohort study of patients treated with bezlotoxumab in Spain was conducted. We compared the characteristics of cohort patients with those of patients treated with bezlotoxumab in the pivotal MODIFY trials. We assessed recurrence rates 12 weeks after completion of treatment against C. difficile, and we analysed the factors associated with bezlotoxumab failure. Ninety-one patients were included in the study. The cohort presented with more risk factors for rCDI than the patients included in the MODIFY trials. Thirteen (14.2%) developed rCDI at 12 weeks of follow-up, and rCDI rates were numerically higher in patients with two or more previous episodes (25%) than in those who had fewer than two previous episodes of C. difficile infection (CDI) (10.4%); p = 0.09. There were no adverse effects attributable to bezlotoxumab. Despite being used in a more compromised population than that represented in clinical trials, we confirm the effectiveness of bezlotoxumab for the prevention of rCDI

A novel tool for the evaluation and assessment of demand response activities in the industrial sector

This paper introduces a novel tool for industrial customers to perform a cost-benefit analysis regarding the implementation of Demand Response (DR) strategies in their facilities with the final goal of softening the impact of RES intermittency in the grid. The dynamic simulation tool focuses on assessing the participation of industries in reserve energy markets in the same conditions as generators offering capacity reserve, energy reserve or both of them and taking into account all the technical restrictions of production processes as well as possible extra costs due to the implementation of DR (additional labour cost, productivity losses, etc.) Main innovations of the methodology are the DR assessment carried out per process and the introduction of the margin of decision as a decision making strategy for the energy consumer. Along the paper, the methodology behind this tool is introduced step by step in order to show how the technical, economic and environmental analyses are performed. At the end, it is included the application of the methodology to a real paper factory in Germany. Results of the dynamic simulation tool are provided and discussed, showing the potential of the paper manufacturing in DR programmes as well as the benefits associated to it.This work was completed in the framework of the DRIP project (11ENV/DE/340) co-funded by the European Commission through the LIFE Environment Programme. The authors deeply thank all the participants in the project for their help and support that made possible this work.Rodríguez-García, J.; Álvarez, C.; Carbonell-Carretero, J.; Alcázar-Ortega, M.; Peñalvo López, E. (2016). A novel tool for the evaluation and assessment of demand response activities in the industrial sector. Energy. 113:1136-1146. doi:10.1016/j.energy.2016.07.146S1136114611

Three double-dose reinforced hepatitis B revaccination scheme for patients with cirrhosis unresponsive to the standard regimen: an open-label randomised clinical trial

© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.[Objective] We aimed to compare the response rates between two different hepatitis B virus vaccination schedules for cirrhotic subjects who were non-responders to the first three 40 µg doses (month 0-1-2), and identify factors associated with the final response.[Design] A total of 120 cirrhotic patients (72.5% decompensated) were randomised at a 1:1 ratio to receive a single 40 µg booster vaccination at month 6 (classical arm) versus an additional round of three new 40 µg doses administered at monthly intervals (experimental arm). The main outcome was the rate of postvaccinal anti-hepatitis B surface antibodies levels ≥10 mIU/mL.[Results] Efficacy by ITT analysis was higher in the experimental arm (46.7%) than in the classical one (25%); OR 2.63, p=0.013. The experimental arm increased response rates compared with the classical one from 31% to 68% (OR 4.72; p=0.007), from 24.4% to 50% (OR 3.09; p=0.012) and from 24.4% to 53.8% (OR 3.62; p=0.007), in Child A, Model for End-Stage Liver Disease (MELD) <15 and MELD-Na<15 patients, respectively. Patients with more advanced liver disease did not benefit from the reinforced scheme. Both regimens showed similar safety profiles. Multivariable analysis showed that the experimental treatment was independently response associated when adjusted across three logistic regression models indicating equivalent cirrhosis severity.[Conclusion] For cirrhotic patients, the revaccination of non-responders to the first three dose cycle, with three additional 40 µg doses, achieved significantly better response rates to those obtained with an isolated 40 µg booster dose.[Trial registration number] NCT01884415.This study project was awarded competitive public funding for Independent Research from the Spanish Government Ministry of Health and Social Politics in 2011 via the Carlos III Health Institute (EC11-452). Javier Ampuero is supported by grants from the Carlos III Health Institute (GLD19/00100 and PI19/01404). IBiS was created as a partnership between the Junta of Andalusia Department of Health, the Department of Innovation, Science and Business of the Junta of Andalusia, the Andalusian Health Service, the University of Seville and the Spanish National Research Council.Peer reviewe

Protocolo de manejo de pancreatitis aguda. Hospital Universitario San Ignacio (HUSI) Bogotá

La pancreatitis aguda es la inflamación aguda del páncreas con grado variable de compromiso de los tejidos regionales y diferente grado de compromiso sistémico. Se utilizan como definiciones las establecidas en el consenso de Atlanta.8-2

Aprendizaje-Servicio en el entorno rural de León

[ES] A través del grupo de Innovación Docente BIOMETAC, nace esta experiencia de ApS para promover en los estudiantes de los grados en Biología, Biotecnología y Ciencias Ambientales de la ULE, la iniciativa cívica de participación en la sociedad. El objetivo general del proyecto es que el alumnado aplique sus conocimientos y habilidades para sensibilizar y dinamizar a la población de varios municipios rurales de León frente a retos de la Agenda 2030 asociados a la salud y la sostenibilidad ambiental. Se establecieron 3 grupos de trabajo, cada uno integrado por 12 estudiantes de los tres grados, que trabajan en 3 municipios rurales de la provincia de León: Cistierna, Truchas y Villablino, con diversas problemáticas en el ámbito de la salud y medioambiente. El Proyecto se realiza en tres fases: Preparación, Ejecución y Evaluación y Difusión. Durante la primera fase (curso 2021/22), se realizaron reuniones con el alumnado para guiarlos en el diagnóstico de cada municipio. Los datos obtenidos permitieron detectar los problemas que más preocupaban a la población de cada municipio. En una segunda fase (curso 2022/23), los alumnos profundizarán en las distintas problemáticas mediante actuaciones propuestas por ellos mismos y presentarán sus conclusiones en cada municipio. Esta experiencia pretende que los estudiantes pongan los conocimientos y las competencias adquiridas al servicio de comunidades rurales, trabajando directamente sobre varios Objetivos de Desarrollo Sostenible (ODS), mejorando su capacidad de iniciativa, autonomía en la organización del trabajo, y responsabilidad para la resolución de problemas

Consenso mexicano sobre detección y tratamiento del cáncer gástrico incipiente

El cáncer gástrico representa una de las neoplasias más frecuentes en el aparato digestivo y en la mayoría de los casos es el resultado de la progresión de lesiones premalignas. La detección oportuna de estas lesiones es relevante ya que un tratamiento oportuno brinda la posibilidad de curación. En nuestro país no existía un consenso respecto a la detección temprana del cáncer gástrico, por lo que la Asociación Mexicana de Gastroenterología reunió aun grupo de expertos y realizó el Consenso sobre detección y tratamiento del cáncer gástricoincipiente (CGI) para establecer recomendaciones de utilidad para la comunidad médica. Eneste consenso se utilizó la metodología Delphi y se emitieron 38 recomendaciones al respectodel CGI. El consenso define el CGI como aquel que al momento del diagnóstico se encuentralimitado a la mucosa y a la submucosa, independientemente de metástasis en ganglios linfáticos.En México, como otras partes del mundo, los factores asociados al CGI incluyen la infección porHelicobacter pylori, los antecedentes familiares, el tabaquismo y los factores dietéticos. Para eldiagnóstico se recomienda utilizar cromoendoscopia, magnificación y equipos con luz mejorada.Un diagnóstico histopatológico preciso es invaluable para tomar de decisiones terapéuticas. Eltratamiento endoscópico del CGI, ya sea disección o resección de la mucosa, debe ser preferidoal manejo quirúrgico cuando se puedan obtener resultados semejantes en términos de curaciónoncológica. La vigilancia endoscópica se deberá de individualizar

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio